Total Payments
$211,066
2024 Payments
$184.09
Companies
22
Transactions
125
Medicare Patients
232
Medicare Billing
$26,649
Payment Breakdown by Category
Consulting$89,333 (42.3%)
Research$50,317 (23.8%)
Other$45,245 (21.4%)
Travel$23,348 (11.1%)
Food & Beverage$2,824 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $89,333 | 32 | 42.3% |
| Unspecified | $50,317 | 10 | 23.8% |
| Grant | $30,000 | 3 | 14.2% |
| Travel and Lodging | $23,348 | 28 | 11.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $10,000 | 1 | 4.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,745 | 4 | 2.2% |
| Food and Beverage | $2,824 | 46 | 1.3% |
| Honoraria | $500.00 | 1 | 0.2% |
Payments by Type
General
$160,749
115 transactions
Research
$50,317
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $38,134 | 16 | $0 (2023) |
| Merz Pharmaceuticals, LLC | $37,642 | 4 | $0 (2022) |
| US WorldMeds, LLC | $34,691 | 16 | $0 (2020) |
| Ipsen Pharma SAS | $30,036 | 6 | $0 (2018) |
| Allergan, Inc. | $17,404 | 30 | $0 (2021) |
| MDD US Operations, LLC | $14,625 | 7 | $0 (2022) |
| Medtronic, Inc. | $10,185 | 8 | $0 (2023) |
| Abbott Laboratories | $9,229 | 19 | $0 (2021) |
| GlaxoSmithKline, LLC. | $5,200 | 1 | $0 (2021) |
| Ipsen Biopharmaceuticals, Inc | $4,480 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $184.09 | 2 | ABIOMED ($118.55) |
| 2023 | $4,230 | 8 | Kyowa Kirin, Inc. ($3,000) |
| 2022 | $51,682 | 26 | Merz Pharmaceuticals, LLC ($35,692) |
| 2021 | $45,325 | 36 | Medtronic, Inc. ($10,070) |
| 2020 | $12,450 | 4 | AbbVie Inc. ($10,000) |
| 2019 | $42,277 | 15 | US WorldMeds, LLC ($32,241) |
| 2018 | $27,256 | 6 | Ipsen Pharma SAS ($14,693) |
| 2017 | $27,662 | 28 | Ipsen Pharma SAS ($15,342) |
All Payment Transactions
125 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/08/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $65.54 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 04/18/2024 | ABIOMED | Impella (Device) | Food and Beverage | In-kind items and services | $118.55 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/09/2023 | AbbVie Inc. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 07/19/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $125.82 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 07/19/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $125.82 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 07/19/2023 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $49.65 | General |
| Category: Immunology | ||||||
| 07/18/2023 | AbbVie Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $49.62 | General |
| Category: NEUROSCIENCE | ||||||
| 07/17/2023 | Kyowa Kirin, Inc. | Nourianz (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Adenosine A2A Receptors | ||||||
| 04/25/2023 | Medtronic, Inc. | PERCEPT PC BRAINSENSE (Device) | Food and Beverage | In-kind items and services | $18.79 | General |
| Category: Deep Brain Neurostimulation | ||||||
| 01/14/2023 | Takeda Pharmaceuticals U.S.A., Inc. | GAMMAGARD LIQUID (Biological) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2022 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | — | Cash or cash equivalent | $12,341.95 | Research |
| Study: Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Period to Investigate the Efficacy and Safety of NT 201 in the Unilateral and Bilateral Treatment of Essential Tremor of the Upper Limb • Category: Musculoskeletal | ||||||
| 11/25/2022 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | — | Cash or cash equivalent | $10,000.00 | Research |
| Study: Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Period to Investigate the Efficacy and Safety of NT 201 in the Unilateral and Bilateral Treatment of Essential Tremor of the Upper Limb • Category: Musculoskeletal | ||||||
| 11/03/2022 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | — | Cash or cash equivalent | $13,349.79 | Research |
| Study: Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Period to Investigate the Efficacy and Safety of NT 201 in the Unilateral and Bilateral Treatment of Essential Tremor of the Upper Limb • Category: Musculoskeletal | ||||||
| 08/30/2022 | MDD US Operations, LLC | MYOBLOC (Drug) | — | Cash or cash equivalent | $162.50 | Research |
| Study: A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MYOBLOC IN THE TREATMENT OF ADULT LOWER LIMB SPASTICITY FOLLOWED BY AN OPEN-LABEL EXTENSION, MULTIPLE-TREATMENT SAFETY STUDY OF MYOBLOC • Category: NEUROLOGY | ||||||
| 08/26/2022 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 08/26/2022 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $1,025.96 | General |
| Category: FACIAL AESTHETICS | ||||||
| 08/26/2022 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $76.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 08/26/2022 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $24.34 | General |
| Category: FACIAL AESTHETICS | ||||||
| 08/23/2022 | MDD US Operations, LLC | MYOBLOC (Drug) | — | Cash or cash equivalent | $1,137.50 | Research |
| Study: A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MYOBLOC IN THE TREATMENT OF ADULT LOWER LIMB SPASTICITY FOLLOWED BY AN OPEN-LABEL EXTENSION, MULTIPLE-TREATMENT SAFETY STUDY OF MYOBLOC • Category: NEUROLOGY | ||||||
| 08/11/2022 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 08/03/2022 | MDD US Operations, LLC | MYOBLOC (Drug) | — | Cash or cash equivalent | $1,300.00 | Research |
| Study: A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MYOBLOC IN THE TREATMENT OF ADULT LOWER LIMB SPASTICITY FOLLOWED BY AN OPEN-LABEL EXTENSION, MULTIPLE-TREATMENT SAFETY STUDY OF MYOBLOC • Category: NEUROLOGY | ||||||
| 07/19/2022 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $45.04 | General |
| Category: NEUROSCIENCE | ||||||
| 06/09/2022 | Medtronic, Inc. | PERCEPT PC BRAINSENSE (Device) | Food and Beverage | In-kind items and services | $36.64 | General |
| Category: Deep Brain Neurostimulation | ||||||
| 06/06/2022 | Medtronic, Inc. | PERCEPT PC BRAINSENSE (Device) | Food and Beverage | In-kind items and services | $25.24 | General |
| Category: Deep Brain Neurostimulation | ||||||
| 06/05/2022 | Medtronic, Inc. | PERCEPT PC BRAINSENSE (Device) | Food and Beverage | In-kind items and services | $23.37 | General |
| Category: Deep Brain Neurostimulation | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Period to Investigate the Efficacy and Safety of NT 201 in the Unilateral and Bilateral Treatment of Essential Tremor of the Upper Limb | Merz Pharmaceuticals, LLC | $35,692 | 3 |
| A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-TREATMENT EFFICACY AND SAFETY STUDY OF MYOBLOC IN THE TREATMENT OF ADULT LOWER LIMB SPASTICITY FOLLOWED BY AN OPEN-LABEL EXTENSION, MULTIPLE-TREATMENT SAFETY STUDY OF MYOBLOC | MDD US Operations, LLC | $14,625 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 66 | 173 | $66,474 | $8,662 |
| 2022 | 2 | 42 | 115 | $42,067 | $5,157 |
| 2021 | 3 | 53 | 143 | $57,460 | $7,294 |
| 2020 | 4 | 71 | 128 | $46,249 | $5,536 |
Total Patients
232
Total Services
559
Medicare Billing
$26,649
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Facility | 2023 | 15 | 46 | $41,652 | $4,645 | 11.2% |
| 64642 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | Facility | 2023 | 11 | 24 | $12,936 | $1,736 | 13.4% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Facility | 2023 | 29 | 81 | $4,054 | $1,142 | 28.2% |
| 64643 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | Facility | 2023 | 11 | 22 | $7,832 | $1,139 | 14.5% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Facility | 2022 | 16 | 43 | $36,972 | $4,179 | 11.3% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Facility | 2022 | 26 | 72 | $5,095 | $978.05 | 19.2% |
| 64616 | Injection of chemical for destruction of nerve muscles on one side of neck excluding voice box accessed through the skin | Facility | 2021 | 15 | 41 | $35,568 | $4,111 | 11.6% |
| 64642 | Injection of chemical for destruction of nerve muscles on one arm or leg, 1-4 muscles | Facility | 2021 | 11 | 31 | $16,709 | $2,182 | 13.1% |
| 95874 | Needle measurement and recording of electrical activity of muscles for guidance with injection of chemical for destruction of muscles | Facility | 2021 | 27 | 71 | $5,183 | $1,002 | 19.3% |
| 64616 | Injection of chemical for destruction of nerve muscles on one side of neck excluding voice box accessed through the skin | Facility | 2020 | 15 | 36 | $32,760 | $3,304 | 10.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 13 | 13 | $5,444 | $894.45 | 16.4% |
| 95874 | Needle measurement and recording of electrical activity of muscles for guidance with injection of chemical for destruction of muscles | Facility | 2020 | 25 | 60 | $4,380 | $791.68 | 18.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 18 | 19 | $3,665 | $545.65 | 14.9% |
About Dr. Philip Charles, MD
Dr. Philip Charles, MD is a Neurological Surgery healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851483267.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Philip Charles, MD has received a total of $211,066 in payments from pharmaceutical and medical device companies, with $184.09 received in 2024. These payments were reported across 125 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($89,333).
As a Medicare-enrolled provider, Charles has provided services to 232 Medicare beneficiaries, totaling 559 services with total Medicare billing of $26,649. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurological Surgery
- Other Specialties Neurology
- Location Nashville, TN
- Active Since 09/30/2006
- Last Updated 10/25/2020
- Taxonomy Code 207T00000X
- Entity Type Individual
- NPI Number 1851483267
Products in Payments
- Xeomin (Biological) $37,642
- MYOBLOC (Biological) $34,191
- BOTOX (Biological) $23,333
- Dysport 300 U-1 (Drug) $15,342
- Dysport (Drug) $14,693
- MYOBLOC (Drug) $14,625
- ACTIVA (Device) $10,036
- IonicRF Generator (Device) $8,955
- BENLYSTA (Biological) $5,200
- DYSPORT (Drug) $4,480
- LYVISPAH (Drug) $3,000
- Nourianz (Drug) $3,000
- MIGRANAL (Drug) $2,500
- BOTOX NEURO REHAB (Drug) $2,206
- NUPLAZID (Drug) $317.18
- DBS IPGs (Device) $130.16
- Impella (Device) $118.55
- PERCEPT PC BRAINSENSE (Device) $115.38
- Briviact (Drug) $113.57
- FIRDAPSE (Drug) $95.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurological Surgery Doctors in Nashville
Dr. Brian O'shaughnessy, Md, MD
Neurological Surgery — Payments: $2.8M
Neurological Surgery $2.8M
Chine Logan, D.o, D.O
Neurological Surgery — Payments: $428,685
Neurological Surgery $428,685
Dr. Scott Parker, M.d, M.D
Neurological Surgery — Payments: $394,938
Neurological Surgery $394,938
Dr. Rohan Chitale, Md, MD
Neurological Surgery — Payments: $175,083
Neurological Surgery $175,083
Gregory Lanford, M.d, M.D
Neurological Surgery — Payments: $152,345
Neurological Surgery $152,345
Dr. Khan Li, M.d, M.D
Neurological Surgery — Payments: $105,930
Neurological Surgery $105,930